Aptissen and KiOmed Pharma forge a strategic alliance bringing breakthrough in Osteoarthritis Treatment
Geneva, Switzerland & Liège, Belgium
Aptissen and KiOmed Pharma, two leaders in the fields of pharmaceutical innovation and regenerative medicine, are proud to announce the signing of a landmark license and supply agreement for the global commercialization of KioMedinevsone—a pioneering single-injection treatment designed for patients suffering from refractory osteoarthritis (OA).
KioMedinevsone offers a unique, chitosan-based therapeutic approach, setting a new standard in OA care by delivering long-lasting relief in just one injection. This agreement marks a significant expansion of the companies’ previous collaboration, which was initially limited to Germany, Italy, and Poland. The new partnership paves the way for broader international access to this cutting-edge treatment and positions the companies to capture growing demand in the global osteoarthritis therapeutics market—projected to reach over $5 billion by 2030.
Aptissen, a Swiss-based pharma leader with a robust global presence in over 70 countries, brings a strong track record in ortho-biologics. With an extensive portfolio of musculoskeletal solutions, the company is committed to improving patient outcomes through next-generation medical technologies. “This agreement represents a major step forward in Aptissen’s growth strategy,” said Silvia Scherer, CEO of Aptissen. “We are leveraging our proven global distribution network and commercial expertise to accelerate access to a product with high clinical and market potential.”
KiOmed Pharma, headquartered in Belgium, specializes in the development of advanced, chitosan-based products for rheumatology, dermatology, and ophthalmology. The company’s proprietary KiOmedine® technology platform is at the core of its innovative pipeline of therapeutic devices. “Our partnership with Aptissen allows KiOmed Pharma to rapidly scale the global impact of KioMedinevsone while focusing on innovation and evidence generation,” said Houtaï Choumane, CEO of KiOmed Pharma. “This agreement further validates our technology platform and ensures long-term value creation.”
Under the new agreement:
- Aptissen will have exclusive rights to market and distribute KioMedinevsone in selected markets and KiOmed Pharma will receive upfront payments, sales milestones, and royalties based on commercial success
- KiOmed Pharma will lead post-market clinical development to continue building evidence and expanding indications.
- Aptissen will spearhead the commercial strategy and global market expansion.
“This strategic partnership signifies more than just a commercial agreement—it’s a shared mission to transform the lives of millions living with osteoarthritis,” stated Gilles Bos and François Blondel, Founders and Chairmen of the Board of, respectively, Aptissen and KiOmed Pharma. “Together, we are accelerating access to a groundbreaking solution that delivers significant pain relief and restores mobility for patients worldwide.”
Contacts
- houtai.choumane@kiomedpharma.com
- +32 4 228 80 40
